Literature DB >> 20033749

Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study.

M Montero1, M Sala, M Riu, F Belvis, M Salvado, S Grau, J P Horcajada, F Alvarez-Lerma, R Terradas, M Orozco-Levi, X Castells, H Knobel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20033749     DOI： 10.1007/s10096-009-0850-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  14 in total

1.  Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.

Authors:  E B El Amari; E Chamot; R Auckenthaler; J C Pechère; C Van Delden
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

Review 2.  The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance.

Authors:  Keith S Kaye; Anthony D Harris; Matthew Samore; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2005-04       Impact factor: 3.254

3.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Clindamycin and metronidazole as independent risk factors for nosocomial acquisition of multidrug-resistant Pseudomonas aeruginosa.

Authors:  R Cipriano Souza; A C Vicente; V V Vieira; S G Marques; M das Graças A Soares; M C L Moura; R J Koifman
Journal:  J Hosp Infect       Date:  2008-06-03       Impact factor: 3.926

5.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

Authors:  Anthony D Harris; Matthew H Samore; Marc Lipsitch; Keith S Kaye; Eli Perencevich; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

6.  Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

7.  Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.

Authors:  A P Zavascki; R P Cruz; L Z Goldani
Journal:  J Hosp Infect       Date:  2005-02       Impact factor: 3.926

8.  Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.

Authors:  José A Martínez; Esther Delgado; Sara Martí; Francesc Marco; Jordi Vila; Josep Mensa; Antoni Torres; Carles Codina; Antoni Trilla; Alex Soriano; Aitor Alquezar; Pedro Castro; José M Nicolás
Journal:  Intensive Care Med       Date:  2008-10-21       Impact factor: 17.440

Review 9.  Pseudomonal infections in patients with COPD: epidemiology and management.

Authors:  David Lieberman; Devora Lieberman
Journal:  Am J Respir Med       Date:  2003

10.  Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity.

Authors:  Elisabeth Paramythiotou; Jean-Christophe Lucet; Jean-François Timsit; Dominique Vanjak; Catherine Paugam-Burtz; Jean-Louis Trouillet; Stéphanie Belloc; Najiby Kassis; Andreas Karabinis; Antoine Andremont
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079
View more
  16 in total

Review 1.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

2.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

3.  Clinical risk factors for admission with Pseudomonas and multidrug-resistant Pseudomonas community-acquired pneumonia.

Authors:  Sadeep Shrestha; Rachael A Lee; Adeniyi J Idigo; J Michael Wells; Matthew L Brown; Howard W Wiener; Russell L Griffin; Gary Cutter
Journal:  Antimicrob Resist Infect Control       Date:  2022-07-14       Impact factor: 6.454

4.  Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study.

Authors:  Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan
Journal:  Infection       Date:  2018-05-11       Impact factor: 3.553

Review 5.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Trimetoprim-sulfametoxazole in ventilator-associated pneumonia: a cohort study.

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Anastasia Purcarea; Catherine Chakvetadze; Astrid de Farcy de Pontfarcy; Gianpiero Tebano; Aurelia Pitsch; Lyvan Vong; Sebastien Jochmans; Christophe Vinsonneau; Mehran Monchi; Sylvain Diamantis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

7.  Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection.

Authors:  Scott T Micek; Nicholas Hampton; Marin Kollef
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition.

Authors:  Eva Morales; Francesc Cots; Maria Sala; Mercè Comas; Francesc Belvis; Marta Riu; Margarita Salvadó; Santiago Grau; Juan P Horcajada; Maria Milagro Montero; Xavier Castells
Journal:  BMC Health Serv Res       Date:  2012-05-23       Impact factor: 2.655

9.  Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.

Authors:  Nazaret Cobos-Trigueros; Mar Solé; Pedro Castro; Jorge Luis Torres; Cristina Hernández; Mariano Rinaudo; Sara Fernández; Álex Soriano; José María Nicolás; Josep Mensa; Jordi Vila; José Antonio Martínez
Journal:  Crit Care       Date:  2015-05-04       Impact factor: 9.097

10.  Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.

Authors:  Matthias Willmann; Anna M Klimek; Wichard Vogel; Jan Liese; Matthias Marschal; Ingo B Autenrieth; Silke Peter; Michael Buhl
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.